Search

BioCryst Pharmaceuticals Inc

Open

SectorHealthcare

8.22 -9.77

Overview

Share price change

24h

Current

Min

8.06

Max

9.18

Key metrics

By Trading Economics

Income

800M

78M

Sales

62M

218M

P/E

Sector Avg

7.603

56.597

EPS

0.3

Profit margin

35.92

Employees

435

EBITDA

799M

99M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+129.77% upside

Dividends

By Acuity

Next Earnings

2 lis 2026

Market Stats

By TradingEconomics

Market Cap

306M

2.5B

Previous open

17.99

Previous close

8.22

News Sentiment

By Acuity

52%

48%

270 / 339 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 wrz 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc. shares are higher in after-market trading, despite a generally flat performance and remaining below their 20-day moving average.

8 wrz 2026, 23:16 UTC

BioCryst Pharmaceuticals shares are higher in after-market hours, despite four consecutive lower closes. No specific news was identified to explain the price movement.

3 wrz 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday. No specific news has been identified to explain the movement.

2 wrz 2026, 23:46 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market sentiment shifts.

1 wrz 2026, 22:26 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market hours following a stable performance. No specific news was identified to explain the price movement.

31 sie 2026, 20:07 UTC

BioCryst Pharmaceuticals Inc shares are lower today amid broader market declines following inflation concerns from the Jackson Hole Economic Symposium.

28 sie 2026, 19:16 UTC

News

BioCryst Pharmaceuticals shares are lower despite reporting Q2 2026 revenue of $218.3 million, reflecting broader market trends and valuation discounts.

27 sie 2026, 20:07 UTC

BioCryst Pharmaceuticals shares are higher as positive jobless claims data boosts market sentiment. The stock stabilized after reaching a session high.

26 sie 2026, 19:36 UTC

Event

BioCryst Pharmaceuticals received marketing approval for ORLADEYO in pediatric patients. Shares are lower today amid broader market trends and inflation data.

24 sie 2026, 19:26 UTC

BioCryst Pharmaceuticals Inc shares are trading higher, maintaining a position above the 20-day moving average and near the midpoint of their one-month range.

21 sie 2026, 22:26 UTC

BioCryst Pharmaceuticals shares moved higher in after-hours trading, reaching a session high before slightly retracing. No specific news was identified to explain the movement.

20 sie 2026, 20:01 UTC

Correlated Moves
Social Media

BioCryst Pharmaceuticals Inc shares are lower amid a decline in the Biotechnology sub-sector. Earlier in the session, shares rebounded from a session high.

19 sie 2026, 23:01 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, retracing from an earlier uptick with no specific news identified to explain the decline.

18 sie 2026, 20:06 UTC

BioCryst Pharmaceuticals Inc shares are declining amid broader market weakness, with no specific news identified to explain today's price movement.

14 sie 2026, 19:06 UTC

BioCryst Pharmaceuticals is lower today, following broader market concerns over an unexpected drop in U.S. retail sales impacting Federal Reserve interest rate policy.

13 sie 2026, 21:31 UTC

BioCryst Pharmaceuticals shares traded roughly flat in after-market hours, remaining within their one-month range and above the 20-day moving average.

12 sie 2026, 19:41 UTC

BioCryst Pharmaceuticals shares are higher today, rebounding from an earlier dip and reflecting notable volatility during the session. The stock remains above its 20-day moving average.

11 sie 2026, 23:26 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market weakness and cautious sentiment.

10 sie 2026, 19:51 UTC

News

BioCryst Pharmaceuticals Inc. shares are higher after Wall Street Zen upgraded its rating to "strong-buy." Other firms also adjusted price targets amid market uncertainty.

7 sie 2026, 19:56 UTC

BioCryst Pharmaceuticals is trading higher, continuing a positive trend amid easing concerns over interest rate hikes following a disappointing jobs report.

6 sie 2026, 22:36 UTC

BioCryst Pharmaceuticals shares are lower in after-market trading, continuing a decline since Thursday's close and positioned below the 20-day moving average.

5 sie 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, despite no specific news identified to explain the movement. They remain below their 20-day moving average.

4 sie 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 sie 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 lip 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 lip 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 lip 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 lip 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27 lip 2026, 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24 lip 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

129.77% upside

12 Months Forecast

Average 20.22 USD  129.77%

High 32 USD

Low 11 USD

Based on 9 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

7

Buy

2

Hold

0

Sell

Sentiment

By Acuity

270 / 339 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat